India, July 30 -- VYNE Therapeutics Inc. (VYNE) Wednesday said that its Phase 2b study of Repibresib gel in nonsegmental vitiligo failed to meet its primary goal. Following the news, the company's shares were more than 70% down in pre-market.
The primary endpoint was the proportion of subjects achieving an improvement in Facial Vitiligo Area Scoring Index of at least 50% from baseline at week 24 compared to vehicle.
Based on these data, the company has decided to discontinue the extension phase of the study.
VYNE Therapeutics stock had closed at $1.44, down 0.69% on Tuesday. It has traded in the range of $0.85 - $4.30 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services w...